These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 32572190)

  • 1. Development of CAR-T cell therapies for multiple myeloma.
    Gagelmann N; Riecken K; Wolschke C; Berger C; Ayuk FA; Fehse B; Kröger N
    Leukemia; 2020 Sep; 34(9):2317-2332. PubMed ID: 32572190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
    Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
    Front Immunol; 2019; 10():1613. PubMed ID: 31379824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
    Jasiński M; Basak GW; Jedrzejczak WW
    Front Immunol; 2021; 12():632937. PubMed ID: 33717171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
    Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M
    Haematologica; 2021 Aug; 106(8):2054-2065. PubMed ID: 33792221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
    Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cell therapies for patients with multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Nat Rev Clin Oncol; 2021 Feb; 18(2):71-84. PubMed ID: 32978608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
    Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
    Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
    Choi T; Kang Y
    Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
    Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
    J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
    Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
    Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-cell therapy: is it prime time in myeloma?
    Sidana S; Shah N
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):260-265. PubMed ID: 31808895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T-cell therapy for multiple myeloma: state of the art and prospects.
    van de Donk NWCJ; Usmani SZ; Yong K
    Lancet Haematol; 2021 Jun; 8(6):e446-e461. PubMed ID: 34048683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
    Beauvais D; Danhof S; Hayden PJ; Einsele H; Yakoub-Agha I
    Curr Opin Oncol; 2020 Sep; 32(5):418-426. PubMed ID: 32740095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.